Business
ANI Pharmaceuticals Reports Record Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Financial Guidance
Record quarterly and full year net revenues of $247.1 million and $883.4 million, up 29.6% and 43.8% year-over-year, respectivelyTotal Rare Disease quarterly and full year net revenue of $131.3 million and $422.6 million, up 50.8% and 84.1% year-over-year, respectively Quarterly and full year Purified Cortrophin® Gel net revenues of $111.4 million and $347.8 million, up 87.6% and 75.6% year-over-year, respectivelyQuarterly and full year ILUVIEN® and YUTIQ® net revenues of $19.8 million and $74.9
About this update from Ani Pharmaceuticals, Inc.
[{"type":"image","alt":"ANI Pharmaceuticals, Inc.","displaySize":"","headline":null,"caption":"ANI Pharmaceuticals, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":270,"height":114,"url":"https://media.zenfs.com/en/globenewswire.com/affa8ae63629bff3d190d327bdae162e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ropAbm4enKilJXBFvyz.RQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3NztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/affa8ae63629bff3d190d327bdae162e","width":270,"height":114}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Record quarterly and full year net revenues of $247.1 million and $883.4 million, up 29.6% and 43.8% year-over-year, respectively","length":129,"tagName":"p"}]},{"val":[{"type":"text","content":"Total Rare Disease quarterly and full year net revenue of $131.3 million and $422.6 million, up 50.8% and 84.1% year-over-year, respectively","length":140,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Quarterly and full year Purified Cortrophin® Gel net revenues of $111.4 million and $347.8 million, up 87.6% and 75.6% year-over-year, respectively","length":147,"tagName":"p"}]},{"val":[{"type":"text","content":"Quarterly and full year ILUVIEN® and YUTIQ® net revenues of $19.8 million and $74.9 million, respectively(1)","length":108,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":255,"olType":false}]},{"val":[{"type":"text","content":"Quarterly and full year GAAP net income available to common shareholders of $27.5 million and $77.2 million, respectively","length":121,"tagName":"p"}]},{"val":[{"type":"text","content":"Record quarterly and full year adjusted non-GAAP EBITDA of $65.4 million and $229.8 million, up 30.6% and 47.3% year-over-year, respectively","length":140,"tagName":"p"}]},{"val":[{"type":"text","content":"Quarterly diluted GAAP income per share of $1.18 and adjusted non-GAAP diluted earnings per share of $2.33; full year diluted GAAP income per share of $3.32 and adjusted non-GAAP diluted earnings per share of $7.89","length":214,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":999,"olType":false},{"type":"text","content":"PRINCETON, N.J., Feb. 27, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the fourth qua...